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Abstract 
 
Aims: To assess whether a structured diabetes education programme, Patient Empowerment 
Programme (PEP), was associated with a lower risk of first cardiovascular disease (CVD) 
event and all-cause mortality in a population-based cohort of type 2 diabetes mellitus 
(T2DM) patients in primary care. 
Methods and Methods: A Chinese cohort of 27,278 T2DM patients without prior 
occurrence of CVD events on or before baseline study recruitment date was linked to the 
Hong Kong administrative database from 2008 to 2013. PEP was provided to T2DM 
patients treated at primary care outpatient clinics through community trained professional 
educators. Non-PEP participants were matched one-to-one with the PEP participants using 
propensity score method with respect to their baseline covariates. Cox proportional hazard 
regressions were performed to estimate the associations of PEP with the occurrence of first 
CVD event, coronary heart disease, stroke, heart failure and death from any cause, 
controlling for baseline characteristics.  
Results: During a median of 21.5 months follow-up, 795 (352 PEP participants and 443 
non-PEP participants) patients suffered a first CVD event. After adjusting for confounding 
variables, PEP participants had a lower incidence of all-cause mortality (hazard ratio: 0.564; 
95%CI:0.445-0.715; P<0.001), first CVD (hazard ratio: 0.807; 95%CI:0.696-0.935; P=0.004) 
and stroke (hazard ratio: 0.702; 95%CI:0.569-0.867; P=0.001) events than those without 
PEP.  
Conclusions:  Enrolment in PEP was associated with reduced all-cause mortality and first 
CVD events among T2DM patients. The CVD benefit of PEP might be attributable to 
improving metabolic control through empowerment of self-care and enhancement of quality 
of diabetes care in primary care. 
 
Word Count: 250 
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Manuscript Text 
 
Introduction 
 
Type 2 diabetes mellitus (T2DM) is a global epidemic that contributes to a significant 
burden of disease worldwide[1]. The rapid increase in T2DM prevalence over the past few 
decades[2] has led to the projection of 592 million patients by 2035[1]. Improvements in 
metabolic control, mediated by healthy lifestyle behaviors including physical and healthy 
diet activity, play an important role in managing T2DM by preventing and delaying disease 
progression of cardiovascular complications.  
 
Besides conventional approaches such as pharmaceutical interventions and optimal 
medication, self-management education is an empowering process that teaches patients to 
initiate behavioral changes and strengthen management of their disease[3, 4]. With respect 
to diabetes, self-management education refers to “the ongoing process of facilitating the 
knowledge, skills, and ability necessary for diabetes self-care”.[5] Despite considerable 
variations in the organization of structured diabetes self-management education, systematic 
reviews[6-8] and meta-analyses[9-11] have demonstrated improvements in glycemic and 
cardiovascular risk factor control in both individual and group-based patient education 
interventions.  
 
Significant reduction in diabetes-related complications as a result of diabetes education in 
secondary care setting was found. In a systematic review of randomized controlled trials on 
educational interventions for T2DM[6], studies focused on the effect of diabetes education 
on metabolic control and intake of oral hypoglycaemic treatment. To date, only one study[12] 
investigated the effect of diabetes education on long-term cardiovascular disease outcomes. 
Thus, the study (structured intensive diabetes education programme, SIDEP) [12] on a 
sample of 547 Korean patients with T2DM under secondary care, reported that patients with 
intensive diabetes education programme, at a follow-up of beyond four years, had lower 
frequency of hospital admissions related to diabetic complications than those who did not 
take part in the programme. However, whether or not diabetes education in primary care 
settings has had a significant impact on reducing incidence of cardiovascular disease 
outcomes and mortality remains uncertain. There is paucity of large population-based 
studies on the long-term cardiovascular benefits associated with diabetes education 
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programme in a primary care setting. A recent study[13] on the impact of a Patient 
Empowerment Programme (PEP) intervention on metabolic control provides evidence 
supporting the value of structured diabetes education for T2DM patients in primary care 
settings. Given the significant improvements in metabolic control associated with PEP, we 
evaluated whether those benefits would translate into a reduction in cardiovascular disease 
events.  
 
This population-based propensity matched cohort study was carried out to evaluate the 
influence of implementing PEP in a primary care versus the usual clinical practice. The risks 
of incidence of cardiovascular disease and all-cause mortality events between the PEP and 
usual clinical practice were compared. It was hypothesized that PEP participants would have 
significantly lower risks of cardiovascular disease and all-cause mortality events. 
 
Methods 
 
PEP was launched in 2010 as a tertiary-wide primary care service component across the 
Hong Kong Hospital Authority with the purpose of providing quality chronic disease 
management to enhance primary care services. In the first evaluation cycle, from 1 March, 
2010 to 30 September, 2010, two non-government organizations (NGOs) who were highly 
experienced in providing community medical education services, were invited to participate 
in the programme. From August 2011 onwards, four NGOs were invited to deliver PEP, 
offering full coverage of services across all district clusters in Hong Kong. A detailed 
description of the PEP setting, mode of education delivery and results from the first 
evaluation has been previously published[13]. The main function of PEP is to deliver 
sessions on disease-specific knowledge, self-management skills, self-efficacy and lifestyle 
modification to T2DM patients. This analysis summarized the second set of evaluation data 
derived from the quality of care evaluation of PEP provided by four NGOs with subsidies. 
This analysis included patients who attended at least one session of PEP from 1 March, 2010 
to 30 June, 2012.  
 
Subjects 
 
Subjects with T2DM were selected from a population-based cohort of attendees of general 
outpatient clinics across Hong Kong Hospital Authority, the largest health service provider 
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in Hong Kong. All subjects with T2DM who attended at least one PEP session and had 
post-assessment conducted at 12 months from baseline were included in the outcome 
evaluation. The T2DM subjects were identified with the International Classification of 
Primary Care-2 (ICPC-2) code ‘T90’, through the Hospital Authority’s clinical 
management system database. A total of 17,839 T2DM subjects who had enrolled in PEP 
and attended at least one PEP session between 1 March, 2010 and 30 June, 2012 were 
included in the evaluation of incidence in CVD outcomes. Out of 193,765 T2DM subjects 
(PEP: 17,839, non-PEP: 175,926) within the database, 11,824 subjects (PEP: 756, non-
PEP: 11,068) were excluded due to prior diagnosis of CVD before baseline. Each patient 
was observed from baseline until the incidence of a CVD event, death from any cause, or 
the date of last follow-up of general outpatient clinics as censoring, or 30 June, 2013, 
whichever came first. To evaluate the net effect of PEP post-intervention, 13,639 T2DM 
patients who had never participated in PEP on or before 30 June, 2013 were matched to 
PEP subjects on propensity score matching (described below) as non-PEP group. 
 
We defined the subjects as having a history of co-morbidities and diagnosis of CVD 
according to the diagnosis coding system of International Classification of Diseases, Ninth 
Edition, Clinical Modification (ICD-9-CM) and International Classification of Primary 
Care (ICPC-2) in the clinical management system database of the Hong Kong Hospital 
Authority. The complementary use of ICPC-2 and ICD-9-CM diagnosis coding systems 
was able to capture the history of co-morbidities and diagnosis of CVD in both primary 
and secondary care settings. 
 
Ethics approval of this study was granted by the institutional review board and clinical 
trial registry (NCT01935349, ClinicalTrials.gov). 
 
Cardiovascular Disease  
 
In this study, five outcome events were of interest: 1) first CVD event with one of the 
following diagnoses: coronary heart disease (CHD), stroke, or heart failure, 2) CHD, 3) 
stroke, 4) heart failure, and 5) all-cause mortality. Incidence of CHD was defined as the 
earliest date of diagnosis with ICD-9-CM of 410.x-414.x, 427.5, 798.1, 798.2 or 798.9. 
Incidence of stoke was defined as the earliest date of diagnosis with either ICPC-2 of K89-
K91 or ICD-9-CM of 430, 431, 432.0, 432.1, 432.9, 433.00, 433.01, 433.10, 433.11, 
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433.20, 433.21, 433.30, 433.31, 433.80, 433.81, 433.90, 433.91, 434.00, 434.01, 434.10, 
434.11, 434.90, 434.91, 435.0, 435.1, 435.9, 436 or 438. Incidence of heart failure was 
defined as the earliest date of diagnosis with either ICPC-2 of K77 or ICD-9-CM of 428.0, 
428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 
428.42, 428.43 or 428.9. Incidence of first CVD event was defined as the earliest date of 
diagnosis with any one of the CVD events. 
 
Baseline Covariates 
 
Covariates of patients included the collection of socio-demographic, biomedical data, 
disease characteristics, treatment modalities, and enrolment of co-intervention for diabetes 
[14, 15] at baseline. Socio-demographic characteristics of patients included sex, age, 
smoking status, alcohol status, and educational level. Biomedical data included body mass 
index (BMI), HbA1C level, blood pressure, lipid profile, triglyceride and estimated 
glomerular filtration rate (eGFR) taken within a six-month period from baseline. Disease 
characteristics included the duration of T2DM, family history of T2DM and the use of 
insulin.  
 
Propensity Score Matching 
 
A propensity score is the conditional probability of being selected for the intervention group 
given the observed covariates[16]. The technique aims to form equivalent PEP intervention 
and non-PEP comparison groups by summarizing relevant baseline characteristics of each 
patient into a single-index variable (the propensity score) and then matching patients in the 
non-PEP comparison pool to patients in the PEP intervention group based on the value of the 
propensity score [17-19]. Correspondingly, the propensity score for each patient was 
generated by logistic regression, modelling the PEP intervention as dependent variable and 
baseline covariates of patients as independent variables. Variables used for propensity score 
matching included sex, age, smoking status, alcohol status, educational level, HbA1c level, 
blood pressure, triglyceride, total cholesterol-to-high density lipoprotein cholesterol ratio, low 
density lipoprotein cholesterol, eGFR, duration of T2DM (≤5 years/ >5-10 years/ >10 years), 
history of hypertension, family history of T2DM, use of insulin and enrolment of co-
intervention. The propensity score mapping was made by using the “psmatch2” command[20] 
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by one-to-one matching with the nearest neighbour and without replacement approach in  
STATA.  
 
Data Analysis 
 
Descriptive statistics were used to calculate the baseline characteristics of socio-
demographic and clinical data in PEP and non-PEP groups after propensity score matching. 
Differences in baseline characteristics between PEP and non-PEP groups were tested using 
independent t-test for continuous variables or Chi-square test for categorical variables. The 
incidence rate of all-cause mortality and CVD events in PEP and non-PEP groups were 
reported. The 95% confidence interval (CI) of incidence rate was constructed based on the 
assumption that the observed incident cases followed a Poisson distribution. 
 
Cox proportional hazards regression was performed to estimate the effect of PEP on the 
dependent variable of first CVD events. Multivariable cox proportional hazards regression 
models in propensity score matching were performed, accounting for all baseline 
characteristics of patients. Sensitivity analysis was performed using the PEP participants 
who completed the programme and propensity matched non-PEP participants. For each 
model, survival curves were estimated by Kaplan-Meier method and their differences 
between PEP and non-PEP groups were compared using the log-rank test. Hazard ratio 
(HR) and its 95% confidence intervals were reported for each variable in the regression 
models. Predictive accuracy of Cox models was assessed and compared using Harrell’s 
discrimination C-index, ranging from zero to one. A value of 0.5 indicates no predictive 
discrimination, and values of 0 or 1.0 indicate perfect separation of patients[21]. 
Goodness-of-fit for Cox regression model were assessed using Akaike information 
criterion (AIC) and Bayesian information criterion (BIC).  
 
All statistical analyses were performed using STATA Version 13.0 (StataCorp LP. College 
Station, Texas, U.S.). All significance tests were two-tailed and those with a p-value less 
than 0.05 were considered statistically significant. 
 
Results 
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Table 1 shows cohort characteristics after 1:1 propensity score matching. Among 17,083 
T2DM subjects, 13,639 (79.8%) of them were successfully matched with non-PEP 
participants with regard to demographic and clinical characteristics. PEP participants 
(mean=7.3, SD=6.4) had a significantly shorter duration of T2DM than non-PEP 
participants (mean=7.6, SD=6.4) (t=-3.798, P<0.001). More PEP participants enrolled into 
co-intervention on or before baseline date (91% versus 20%, χ2=14055.994, P<0.001) 
whereas more non-PEP participants used insulin during treatment (3% versus 2%, 
χ2=79.191, P<0.001). For sensitivity analysis, 6,153 PEP participants who completed the 
programme were also matched with the non-PEP participants on one-to-one basis. 
Similarly, PEP participants who had completed the programme were more likely to enrol 
in the co-intervention on or before baseline date (91% versus 23%, χ2=5860.232, P<0.001) 
and less likely to use insulin (1.6% versus 3.3%, χ2=35.904, P<0.001) than the non-PEP 
participants. 
 
Table 2 and Figure 1 present Kaplan-Meier survival curves and the number and incidence 
rates of all-cause mortality and CVD events at a median follow-up of 21.5 months (range, 
0.5 to 40.5 months). Among 13,639 PEP participants and non-PEP participants, the former 
generally suffered from fewer cases of all-cause mortality and CVD events. During a total 
of 25,240 person-years for PEP participants and 25,102 person-years for non-PEP 
participants, 335 deaths (113 PEP participants and 222 non-PEP participants) occurred. 
Also, 795 incidences of first CVD event (352 PEP participants and 443 non-PEP 
participants) occurred during a total of 25,035 person-years for PEP participants and 
24,876 person-years for non-PEP participants. Similar findings were obtained for the 
incidence of some cardiovascular diseases such as CHD, stroke and heart failure. 
 
Multivariable cox Regression Model 
 
Multivariable cox regression analyses on the dependent variable of all-cause mortality and 
cardiovascular disease events are shown in Table 3. After adjusting for confounding 
variables, PEP participants were associated with a lower risk of all-cause mortality 
(HR=0.564, 95%CI: 0.445-0.715, P<0.001) than non-PEP participants. Log-rank test 
suggested that there was a significant difference in the survival time between the two 
groups (χ2=35.65, P<0.001). Moreover, PEP participants were also associated with a lower 
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incidence of first CVD event (HR=0.807, 95%CI: 0.696-0.935, P=0.004) than the non-
PEP participants and the difference in survival time was significant (χ2=10.61, P=0.001). 
 
Sensitivity Analysis 
 
PEP participants who completed the programme were associated with a lower risk of death 
(HR=0.593, 95%CI: 0.406-0.868, P=0.007) than those without PEP. The result of log-rank 
test also evidenced a significant difference in survival time between the two groups 
(χ2=14.02, P<0.001). In addition, participants who completed the PEP were also associated 
with a lower incidence of first CVD event (HR= 0.716, 95%CI: 0.571-0.897, P=0.004) 
than non-PEP participants. The difference in survival time was also significant (χ2=10.15, 
P=0.001). 
 
Discussion 
 
This is the first study investigating the association of a structured diabetes education 
programme with the risk of CVD events and all-cause mortality. The major findings in this 
propensity matched cohort study suggests that lower all-cause mortality was associated 
with the PEP enrolment, in spite of low cumulative (0.0123) and incidence rate (0.665 
cases/ 100 person-years) of all-cause mortality in this population-based cohort. Compared 
with non-PEP participants, PEP participants had only half of mortality events (PEP/non-
PEP: 113/222) and 43.6% lower risk of all-cause mortality (HR=0.564, 95%CI: 0.445-
0.715; P<0.001) after adjusting for socio-demographic and clinical characteristics. 
Moreover, PEP was associated with a reduction in CVD events including stroke and heart 
failure in T2DM patients predominantly managed in primary care setting. Once the T2DM 
patients participated in PEP, all-cause mortality and CVD events occurred less frequently 
within a time span of less than 2 years, regardless of whether the PEP was completed or 
not. The impact of PEP on CVD benefit might be attributable to improvement in 
intermediate outcomes such as metabolic controls through empowerment of self-care and 
enhancement of quality of diabetes care in primary care. 
 
Nonetheless, given the paucity of longitudinal data on observed events among subjects 
with or without diabetes education program, only the association of a diabetes education 
programme with occurrence of diabetes-related hospitalization has been investigated so far 
PEP DM CVD Manuscript 20140917  Page 9 of 15 
Running title: PEP reduced death and CVD events 
[22]. Recent study showed that subjects enrolling in education programme generally had a 
significant HR of 0.10 (95%CI: 0.023-0.438; P=0.002) of being hospitalized due to 
diabetes-related acute events when compared to subjects in control group. The SIDEP[12], 
which was based on T2DM patients on secondary care, reported significantly lower 
diabetes-related hospitalization in those with diabetes education group than those without. 
Diabetes-related acute events may be in part attributed to CVD events but those previous 
studies did not display the breakdown information about the reduction in occurrence of 
CVD events. 
 
Over a period of approximately two-years, our analyzed data investigated not only the 
effect of PEP on observed CVD events, but also the effect of PEP on observed CVD 
subtypes. Interestingly, the effect of PEP differed according to CVD subtypes. The PEP 
interventions did not significantly affect the occurrence of CHD event, but PEP 
participants had significantly lower risk of stroke event (HR=0.702, 95%CI: 0.569-0.867; 
P=0.001) compared with non-PEP participants. The PEP had no significant impact on risk 
association (HR=0.773, 95%CI: 0.558-1.070; P=0.121) in the sensitivity analysis. 
Conversely, the incidence of heart failure was not significantly lower (HR=0.809, 95%CI: 
0.574-1.139; P=0.224) in PEP participants than in non-PEP participants while the risk 
association became borderline significant (HR=0.573, 95%CI: 0.341-0.961; P=0.035) 
upon further selection of participants who completed PEP in the sensitivity analysis. 
Therefore, the increased risk for CVD events for PEP participants compared with non-PEP 
participants was mainly driven by the occurrence of stroke and heart failure, and less by 
the occurrence of CHD. There was no evidence of a significant reduction in CHD events 
among the PEP group compared with the non-PEP group, suggesting that the incidence of 
stroke and heart failure played an important role in the significant effect of PEP on 
incidence of composite first CVD events. Consequently, the current study underlined the 
need for comprehensive outcome evaluation which further breakdown composite CVD 
outcome into subtypes, rather than examination of single composite CVD outcome. 
 
Structured diabetes education curriculum delivered in the PEP group resulted in a 
remarkable reduction by 19.3% and 43.6% in the incidence of CVD events and incidence 
of all-cause mortality, respectively. It is noteworthy that the effect of PEP on the event 
occurrence was comparable with the effect of international randomized controlled trials 
focusing on intensive glucose control. Empirical evidence from population-based 
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randomized controlled trials that had intervened with intensified glucose control therapy 
over a prolonged follow-up period, for instance, UKPDS[23] and Steno-2[24] trial, were 
undoubtedly effective in decreased risk of CVD events and all-cause mortality. However,  
results from ADVANCE trial[25] showed that there was no significant difference in the 
incidence of all-cause mortality between the intervention and control groups although 
intervention was significantly associated with decreased risk of CVD events. Moreover, 
the intensive lifestyle intervention in Look AHEAD trial[26] focusing on overweight or 
obese T2DM were not associated with any reduction  in CVD events, though weight loss 
was significant, after a median of 10-year period. Therefore, this population-based 
propensity matched study demonstrated the beneficial effects of PEP in reducing CVD and 
all-cause mortality events, supporting the public-private partnership and integration of  the 
health sector with NGOs for service delivery in diabetes  care. 
 
Strengths and Limitations of this study 
 
The strengths of this study included the use of a population-based cohort of patients with 
T2DM in Hong Kong Hospital Authority administrative database that was highly 
representative of the Hong Kong general population. Since the clinical characteristics were 
well captured by the administrative database through routine clinical practice, this allowed 
for the consideration of important baseline covariates such as physical assessment, 
laboratory results, diabetes-related medical history, and drugs dispensed for propensity 
score matching. Given the control of baseline covariates achieving balance in the PEP and 
non-PEP groups, propensity score matching was applied to offset the selection bias in this 
sample. 
 
There were several limitations in this study. First, the current study was not a randomized 
controlled trial so it could not eliminate bias in the PEP group on outcomes.  The clinical 
data coming from the ‘real-world’ setting were extracted from routinely collected medical 
records in an administrative database that was not specially designed for this cohort study.  
Both the PEP and non-PEP participants with available baseline covariates were 
presumably included in the analysis. Therefore, the unobserved baseline covariates were 
not taken into account for analysis.  Many subjects in the PEP group had also participated 
in a concurrent multi-disciplinary risk assessment and management program[14, 15] that 
might have added benefit to CVD outcomes.  To confirm the benefit of PEP, a multi-
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center cluster randomized controlled trial, the strongest study design implemented in 
DESMOND[27], would be required. However, it may not be possible to conduct such a 
high-evidence trial in the ‘real-world’ primary care setting. Second, the long-term benefits 
of PEP on outcomes still remains uncertain after the second year. A longer follow-up 
period of beyond 21.5 months on the sustained benefits of outcomes in the intervention 
group compared to control group will be studied. Third, not all PEP participants were 
included in the analysis due to missing values. Therefore the propensity score could not be 
calculated. However, about 80% of eligible PEP participants were included in the analysis. 
Finally, data from this study was not entirely representative of Chinese populations in 
other parts of the world, or those under secondary care or in the private sector.  However, 
findings were generated from a large population-based database of the public service that 
manage over 50% of diabetic patients in Hong Kong. 
 
Conclusion 
 
In conclusion, the findings of this study showed that enrolment in the Patient 
Empowerment Programme (PEP) was associated with decreased all-cause mortality and 
CVD events, especially with stroke and heart failure, in patients with T2DM. Programme 
completion was related to the reductions in CVD events. Results of this study provided 
evidence that a structured diabetes education programme led to at least a short-term  
reduction of CVD and deaths from any cause, in addition to the benefits on metabolic 
control and quality of primary care among T2DM patients . Future studies about the long-
term benefits of PEP on mortality and CVD outcomes are warranted. 
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Table 1. Socio-demographic and Clinical Characteristics of Subjects at Baseline
Factor PEP(N=13,639)
Non-PEP
(N=13,639) P-value
PEP
(N=6,153)
Non-PEP
(N=6,153) P-value
Socio-demographic
sex, % 0.45 0.83
female 58 59 59 59
male 42 41 41 41
age (mean±SD), year 65±9.8 65±11 0.26 65±9.4 65±11 0.99
smoking status, % 0.09 0.35
non-smoker 95 95 96 96
smoker 5 5 4 4
alcohol status, % 0.61 0.70
non-drinker 81 81 81 80
drinker 19 19 19 20
educational level, % 0.91 0.67
no formal education/ primary 53 53 51 51
secondary/ tertiary 47 47 49 49
Biomedical data at baseline (mean±SD)
BMI, kg/m2 25.6±3.9 26.0±4.0 0.17 25.5±3.9 25.6±3.9 0.24
HbA1c, % 7.4±1.3 7.4±1.5 0.22 7.4±1.2 7.3±1.3 0.34
systolic blood pressure, mmHg 134±17 134±16 0.33 135±18 135±17 0.65
diastolic blood pressure, mmHg 75±10 75±10 0.88 75±10 75±10 0.64
triglyceride, mmol/L 1.6±0.96 1.6±1.1 0.96 1.6±1.0 1.6±1.1 0.56
TC/HDL-C ratio 4.0±1.2 4.0±1.1 0.78 4.0±1.2 4.0±1.1 0.88
LDL-C, mmol/L 2.9±0.81 2.9±1.0 0.63 2.9±0.82 2.9±1.1 0.40
eGFR, ml/min/1.73m2 85±20 84±25 0.51 85±20 85±24 0.42
Clinical
duration of T2DM, year 7.3±6.4 7.6±6.4 <0.01* 7.3±6.5 7.5±6.3 0.17
duration of T2DM, % 0.90 0.98
≤5 years 49 50 50 50
5-10 years 25 25 24 24
>10 years 26 25 26 26
history of hypertension, % 15 15 0.85 15 15 0.49
family history of T2DM, % 0.77 0.76
yes 43 44 43 43
no 9 9 8 8
unknown 48 47 49 49
insulin used, % 1.6 3.3 <0.01* 1.5 3.2 <0.01*
enrolment of co-intervention
on/before baseline, % 91 20 <0.01* 91 23 <0.01*
Note:
* p-value<0.05
PEP Participants vs non-PEP PEP Completers vs non-PEP
PEP=Patient Empowerment Programme; BMI=Body mass index; HDL=High-density lipoprotein; TC=Total
cholesterol; LDL=Low-density lipoprotein; eGFR=Epidermal growth factor receptor; T2DM=Type 2
Diabetes Mellitus;
Table 2. Number and incidence rates of all-cause mortality and cardiovascular disease events at a median follow-up of 21.5 months
Event
Cases with
event Estimate 95% CI* Person-years
PEP Participants (N=13,639)
All-cause mortality 113 0.448 (0.369,0.538) 25240
CVD 352 1.406 (1.263,1.561) 25036
CHD 155 0.616 (0.523,0.721) 25174
Stroke 161 0.641 (0.546,0.748) 25128
Heart failure 59 0.234 (0.178,0.302) 25207
Non-PEP Participants (N=13,639)
All-cause mortality 222 0.884 (0.772,1.009) 25102
CVD 443 1.781 (1.619,1.955) 24876
CHD 178 0.711 (0.610,0.823) 25048
Stroke 230 0.921 (0.806,1.049) 24961
Heart failure 98 0.391 (0.317,0.476) 25064
Note:
PEP=Patient Empowerment Programme; CVD=Cardiovascular Disease; CHD=Coronary Heart Disease; CI=Confidence Interval
* The 95%CI was constructed based on Poisson Distribution
Incidence rate (Cases/ 100 person-years)
Table 3. Multivariate Cox proportional hazard regression on the dependent variable of all-cause mortality and cardiovascular disease events
HR† 95%CI P-value
PEP Participants vs non-PEP Participants (N=27,278)
All-cause mortality 0.564 (0.445,0.715) <0.001* 0.799 (0.772,0.825)
CVD 0.807 (0.696,0.935 0.004* 0.730 (0.712,0.749)
CHD 0.840 (0.670,1.054 0.132 0.741 (0.714,0.769)
Stroke 0.702 (0.569,0.867 0.001* 0.721 (0.694,0.747)
Heart failure 0.809 (0.574,1.139 0.224 0.874 (0.846,0.901)
Sensitivity Analysis, PEP Completers vs non-PEP Participants (N=12,306)
All-cause mortality 0.593 (0.406,0.868 0.007* 0.818 (0.783,0.852)
CVD 0.716 (0.571,0.897 0.004* 0.749 (0.724,0.774)
CHD 0.716 (0.503,1.019 0.063 0.769 (0.731,0.807)
Stroke 0.773 (0.558,1.070 0.121 0.747 (0.712,0.783)
Heart failure 0.573 (0.341,0.961 0.035* 0.885 (0.847,0.923)
Note:
HR=Hazard Ratio; CVD=Cardiovascular Disease; CHD=Coronary Heart Disease
† HR>1 indicates greater risk for death of PEP patients compared with non-PEP patients
* p-value<0.05
PEP factor Harrell's C-statistic
Figure 1 Kaplan-Meier Survival Curves for All-cause Mortality and Cardiovascular Disease Events 
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Note: 
CVD - cardiovascular disease 
CHD - coronary heart disease 
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